Cargando…
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802598/ https://www.ncbi.nlm.nih.gov/pubmed/29238044 http://dx.doi.org/10.1038/s41408-017-0018-7 |
| _version_ | 1783298551442309120 |
|---|---|
| author | Nazha, Aziz Sekeres, Mikkael A. Komrokji, Rami Steensma, David P. Kantarjian, Hagop Roboz, Gail Fenaux, Pierre Prebet, Thomas Azarnia, Nozar Zbyszewski, Patrick S. Fruchtman, Steven M. Santini, Valeria Silverman, Lewis R. Platzbecker, Uwe Garcia-Manero, Guillermo |
| author_facet | Nazha, Aziz Sekeres, Mikkael A. Komrokji, Rami Steensma, David P. Kantarjian, Hagop Roboz, Gail Fenaux, Pierre Prebet, Thomas Azarnia, Nozar Zbyszewski, Patrick S. Fruchtman, Steven M. Santini, Valeria Silverman, Lewis R. Platzbecker, Uwe Garcia-Manero, Guillermo |
| author_sort | Nazha, Aziz |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5802598 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58025982018-02-08 Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care Nazha, Aziz Sekeres, Mikkael A. Komrokji, Rami Steensma, David P. Kantarjian, Hagop Roboz, Gail Fenaux, Pierre Prebet, Thomas Azarnia, Nozar Zbyszewski, Patrick S. Fruchtman, Steven M. Santini, Valeria Silverman, Lewis R. Platzbecker, Uwe Garcia-Manero, Guillermo Blood Cancer J Correspondence Nature Publishing Group UK 2017-12-14 /pmc/articles/PMC5802598/ /pubmed/29238044 http://dx.doi.org/10.1038/s41408-017-0018-7 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Nazha, Aziz Sekeres, Mikkael A. Komrokji, Rami Steensma, David P. Kantarjian, Hagop Roboz, Gail Fenaux, Pierre Prebet, Thomas Azarnia, Nozar Zbyszewski, Patrick S. Fruchtman, Steven M. Santini, Valeria Silverman, Lewis R. Platzbecker, Uwe Garcia-Manero, Guillermo Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care |
| title | Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care |
| title_full | Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care |
| title_fullStr | Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care |
| title_full_unstemmed | Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care |
| title_short | Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care |
| title_sort | validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase iii trial of rigosertib vs. best supportive care |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802598/ https://www.ncbi.nlm.nih.gov/pubmed/29238044 http://dx.doi.org/10.1038/s41408-017-0018-7 |
| work_keys_str_mv | AT nazhaaziz validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT sekeresmikkaela validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT komrokjirami validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT steensmadavidp validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT kantarjianhagop validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT robozgail validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT fenauxpierre validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT prebetthomas validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT azarnianozar validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT zbyszewskipatricks validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT fruchtmanstevenm validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT santinivaleria validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT silvermanlewisr validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT platzbeckeruwe validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare AT garciamaneroguillermo validationofaposthypomethylatingagentfailureprognosticmodelinmyelodysplasticsyndromespatientstreatedinarandomizedcontrolledphaseiiitrialofrigosertibvsbestsupportivecare |